A randomized trial of staphylococcus aureus prophylaxis in peritoneal dialysis patients: Mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin

Bernardini, Judith; Piraino, Beth; Holley, Jean Lake; Johnston, James R.; Lutes, R.

doi:10.1016/s0272-6386(96)90105-5

Cited by 214 publications

(181 citation statements)

References 16 publications

Supporting

Mentioning

171

Contrasting

Unclassified

Order By: Relevance

“…A randomized controlled trial showed that daily application of gentamicin cream to the exit site was highly effective in reducing ESI caused by Pseudomonas species, and was as effective as topical mupirocin in reducing S. aureus ESI (107). Two subsequent prospective studies, however, found (108,123).…”

Section: Topical Antibacterial and Antiseptic Agentsmentioning

confidence: 99%

“…In another randomized controlled trial involving pediatric PD patients who were nasal S. aureus carriers, a single course of oral rifampicin plus nasal bacitracin ointment also led to reduction in catheter-related infections (145). In another study, cyclic oral rifampicin and daily topical mupirocin to the exit site were equally effective in reducing the rate of catheter-related infections caused by S. aureus compared with historic control (107). However, adverse reactions to rifampicin were common (107 resistance are also genuine concerns (146).…”

Section: Other Antimicrobial Approachesmentioning

confidence: 99%

See 1 more Smart Citation

ISPD Catheter-Related Infection Recommendations: 2017 Update

et al. 2017

Self Cite

View full text Add to dashboard Cite

Section: Topical Antibacterial and Antiseptic Agentsmentioning

confidence: 99%

Section: Other Antimicrobial Approachesmentioning

confidence: 99%

ISPD Catheter-Related Infection Recommendations: 2017 Update

et al. 2017

Self Cite

View full text Add to dashboard Cite

“…Antibiotic protocols against S. aureus are effective in reducing the risk of S. aureus catheter infections (66)(67)(68)(69)(70)(71)(72)(73)(74)(75)(76)(77)(78)(79)(80)(81) Routine exit-site care by the patient begins when the exit site is well healed; such care is part of the patient's training. Water and antibacterial soap are recommended by many centers.…”

Section: Exit-site Care To Prevent Peritonitismentioning

confidence: 99%

ISPD Position Statement on Reducing the Risks of Peritoneal Dialysis–Related Infections

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…After a follow-up that lasted 1 year in average, a significant reduction in the infection rates of both groups was observed (peritonitis: 33%, ESI: 58%) while no difference between the groups was recorded. 5 Adverse effects due to the use of rifampicin were seen in 12% of the patients using the drug, and mupirocin was recommended as an efficient and alternative treatment to the patients who could not tolerate oral use of rifampicin.…”

Section: Discussionmentioning

confidence: 99%

“…3 As it was shown in the previous studies, the use of prophylactic antibiotics at the exit site or orally (neomycin sulfate, mupirocin, rifampin, TMP-SMX, ciprofloxacin) reduce S. aureus colonization and catheter-related infection rate. [4][5][6][7] In the recent studies, it has been shown that application of mupirocin to the exit site considerably reduces ESI and peritonitis rate. 8,9 Currently, the most popular regimen for mupirocin is to apply it at the exit site once a day, 3-5 times a week.…”

Section: Introductionmentioning

confidence: 99%

Mupirocin application at the exit site in peritoneal dialysis patients: five years of experience

et al. 2010

View full text Add to dashboard Cite

Introduction: In this study, we aimed to analyze the effects of once-or thrice-weekly mupirocin application on peritonitis, exit-site infection (ESI), and antibiotic resistance with mupirocin. Patients and methods: By 2000 mupirocin began to be applied once a week to 33 patients who previously did not use mupirocin at the exit site. By the beginning of 2002, the patients were assigned to two groups. In group I patients continued to apply mupirocin once a week. In group II patients began to apply mupirocin to the exit site three times weekly and we began to obtain cultures from the nares, inguinal area, axillae, and the exit site. Results: A total of 28 episodes of ESI and 41 episodes of peritonitis were seen in 33 patients prior to mupirocin treatment, while a total of 14 episodes of ESI and 34 episodes of peritonitis were observed in all groups of patients who used mupirocin. In a subgroup analysis, 13 episodes of peritonitis and 7 episodes of ESI were determined in group I, while 6 episodes of peritonitis and 1 episode of ESI were determined in group II. Staphylococcus aureus reproduction rate and mupirocin resistance were 2.11 and 0.2%, respectively. Coagulase-negative staphylococcus reproduction rate was 70.56% (MuR: 59.87% and MeR: 33.7%) and 72.6% (MuR: 64.7% and MeR: 33.3%) in groups I and II, respectively. Conclusion: Mupirocin application at the exit sites reduces peritonitis and ESI to a considerable amount, and thrice-weekly application of mupirocin seems to be more efficient compared to once-weekly application.

show abstract

A randomized trial of staphylococcus aureus prophylaxis in peritoneal dialysis patients: Mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin

Cited by 214 publications

References 16 publications

ISPD Catheter-Related Infection Recommendations: 2017 Update

ISPD Catheter-Related Infection Recommendations: 2017 Update

ISPD Position Statement on Reducing the Risks of Peritoneal Dialysis–Related Infections

Mupirocin application at the exit site in peritoneal dialysis patients: five years of experience

Contact Info

Product

Resources

About